{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T13:16:23Z","timestamp":1783602983500,"version":"3.55.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,9]]},"DOI":"10.7759\/cureus.112332","type":"journal-article","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T12:37:31Z","timestamp":1783600651000},"source":"Crossref","is-referenced-by-count":0,"title":["How Biologics Are Changing the Global Burden of Inflammatory Bowel Disease: A Review"],"prefix":"10.7759","author":[{"given":"Yousef","family":"Abu Osba","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanad","family":"Elshebli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah","family":"Abureesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Araek","family":"Al-Shraideh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yousef","family":"Yousef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Abu-Shaban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Abureesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32448-0","article-title":"Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies","volume":"390","author":"Ng SC","year":"2017","unstructured":"Ng SC, Shi HY, Hamidi N, et al.. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2017, 390:2769-78. 10.1016\/S0140-6736(17)32448-0","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(19)30333-4","article-title":"The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"5","year":"2020","unstructured":"The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990-2017. a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol. 2020, 5:17-30. 10.1016\/S2468-1253(19)30333-4","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s00384-024-04711-x","article-title":"Global, regional, and national burden of inflammatory bowel disease, 1990-2021: insights from the Global Burden of Disease 2021","volume":"39","author":"Lin D","year":"2024","unstructured":"Lin D, Jin Y, Shao X, et al.. Global, regional, and national burden of inflammatory bowel disease, 1990-2021: insights from the Global Burden of Disease 2021. Int J Colorectal Dis. 2024, 39:139. 10.1007\/s00384-024-04711-x","journal-title":"Int J Colorectal Dis"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-020-00360-x","article-title":"The four epidemiological stages in the global evolution of inflammatory bowel disease","volume":"18","author":"Kaplan GG","year":"2021","unstructured":"Kaplan GG, Windsor JW. The four epidemiological stages in the global evolution of inflammatory bowel disease. Nat Rev Gastroenterol Hepatol. 2021, 18:56-66. 10.1038\/s41575-020-00360-x","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2020.01.028","article-title":"Changing global epidemiology of inflammatory bowel diseases: sustaining health care delivery into the 21st century","volume":"18","author":"Ananthakrishnan AN","year":"2020","unstructured":"Ananthakrishnan AN, Kaplan GG, Ng SC. Changing global epidemiology of inflammatory bowel diseases: sustaining health care delivery into the 21st century. Clin Gastroenterol Hepatol. 2020, 18:1252-60. 10.1016\/j.cgh.2020.01.028","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31711-1","article-title":"Crohn's disease","volume":"389","author":"Torres J","year":"2017","unstructured":"Torres J, Mehandru S, Colombel JF, Peyrin-Biroulet L. Crohn's disease. Lancet. 2017, 389:1741-55. 10.1016\/S0140-6736(16)31711-1","journal-title":"Lancet"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)32126-2","article-title":"Ulcerative colitis","volume":"389","author":"Ungaro R","year":"2017","unstructured":"Ungaro R, Mehandru S, Allen PB, Peyrin-Biroulet L, Colombel JF. Ulcerative colitis. Lancet. 2017, 389:1756-70. 10.1016\/S0140-6736(16)32126-2","journal-title":"Lancet"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2019.03.017","article-title":"Cytokine networks in the pathophysiology of inflammatory bowel disease","volume":"50","author":"Friedrich M","year":"2019","unstructured":"Friedrich M, Pohin M, Powrie F. Cytokine networks in the pathophysiology of inflammatory bowel disease. Immunity. 2019, 50:992-1006. 10.1016\/j.immuni.2019.03.017","journal-title":"Immunity"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199710093371502","article-title":"A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group","volume":"337","author":"Targan SR","year":"1997","unstructured":"Targan SR, Hanauer SB, van Deventer SJ, et al.. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med. 1997, 337:1029-35. 10.1056\/NEJM199710093371502","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199905063401804","article-title":"Infliximab for the treatment of fistulas in patients with Crohn's disease","volume":"340","author":"Present DH","year":"1999","unstructured":"Present DH, Rutgeerts P, Targan S, et al.. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med. 1999, 340:1398-405. 10.1056\/NEJM199905063401804","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08512-4","article-title":"Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial","volume":"359","author":"Hanauer SB","year":"2002","unstructured":"Hanauer SB, Feagan BG, Lichtenstein GR, et al.. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002, 359:1541-9. 10.1016\/S0140-6736(02)08512-4","journal-title":"Lancet"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa050516","article-title":"Infliximab for induction and maintenance therapy for ulcerative colitis","volume":"353","author":"Rutgeerts P","year":"2005","unstructured":"Rutgeerts P, Sandborn WJ, Feagan BG, et al.. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005, 353:2462-76. 10.1056\/NEJMoa050516","journal-title":"N Engl J Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2006.11.041","article-title":"Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial","volume":"132","author":"Colombel JF","year":"2007","unstructured":"Colombel JF, Sandborn WJ, Rutgeerts P, et al.. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology. 2007, 132:52-65. 10.1053\/j.gastro.2006.11.041","journal-title":"Gastroenterology"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2011.10.032","article-title":"Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis","volume":"142","author":"Sandborn WJ","year":"2012","unstructured":"Sandborn WJ, van Assche G, Reinisch W, et al.. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2012, 142:257-65.e1-3. 10.1053\/j.gastro.2011.10.032","journal-title":"Gastroenterology"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0904492","article-title":"Infliximab, azathioprine, or combination therapy for Crohn's disease","volume":"362","author":"Colombel JF","year":"2010","unstructured":"Colombel JF, Sandborn WJ, Reinisch W, et al.. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med. 2010, 362:1383-95. 10.1056\/NEJMoa0904492","journal-title":"N Engl J Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215734","article-title":"Vedolizumab as induction and maintenance therapy for ulcerative colitis","volume":"369","author":"Feagan BG","year":"2013","unstructured":"Feagan BG, Rutgeerts P, Sands BE, et al.. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013, 369:699-710. 10.1056\/NEJMoa1215734","journal-title":"N Engl J Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215739","article-title":"Vedolizumab as induction and maintenance therapy for Crohn's disease","volume":"369","author":"Sandborn WJ","year":"2013","unstructured":"Sandborn WJ, Feagan BG, Rutgeerts P, et al.. Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med. 2013, 369:711-21. 10.1056\/NEJMoa1215739","journal-title":"N Engl J Med"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1602773","article-title":"Ustekinumab as induction and maintenance therapy for Crohn's disease","volume":"375","author":"Feagan BG","year":"2016","unstructured":"Feagan BG, Sandborn WJ, Gasink C, et al.. Ustekinumab as induction and maintenance therapy for Crohn's disease. N Engl J Med. 2016, 375:1946-60. 10.1056\/NEJMoa1602773","journal-title":"N Engl J Med"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1900750","article-title":"Ustekinumab as induction and maintenance therapy for ulcerative colitis","volume":"381","author":"Sands BE","year":"2019","unstructured":"Sands BE, Sandborn WJ, Panaccione R, et al.. Ustekinumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2019, 381:1201-14. 10.1056\/NEJMoa1900750","journal-title":"N Engl J Med"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00467-6","article-title":"Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials","volume":"399","author":"D'Haens G","year":"2022","unstructured":"D'Haens G, Panaccione R, Baert F, et al.. Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials. Lancet. 2022, 399:2015-30. 10.1016\/S0140-6736(22)00467-6","journal-title":"Lancet"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00466-4","article-title":"Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial","volume":"399","author":"Ferrante M","year":"2022","unstructured":"Ferrante M, Panaccione R, Baert F, et al.. Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial. Lancet. 2022, 399:2031-46. 10.1016\/S0140-6736(22)00466-4","journal-title":"Lancet"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2207940","article-title":"Mirikizumab as induction and maintenance therapy for ulcerative colitis","volume":"388","author":"D'Haens G","year":"2023","unstructured":"D'Haens G, Dubinsky M, Kobayashi T, et al.. Mirikizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2023, 388:2444-55. 10.1056\/NEJMoa2207940","journal-title":"N Engl J Med"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1905725","article-title":"Vedolizumab versus adalimumab for moderate-to-severe ulcerative colitis","volume":"381","author":"Sands BE","year":"2019","unstructured":"Sands BE, Peyrin-Biroulet L, Loftus EV Jr, et al.. Vedolizumab versus adalimumab for moderate-to-severe ulcerative colitis. N Engl J Med. 2019, 381:1215-26. 10.1056\/NEJMoa1905725","journal-title":"N Engl J Med"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00688-2","article-title":"Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial","volume":"399","author":"Sands BE","year":"2022","unstructured":"Sands BE, Irving PM, Hoops T, et al.. Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial. Lancet. 2022, 399:2200-11. 10.1016\/S0140-6736(22)00688-2","journal-title":"Lancet"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)30068-5","article-title":"Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial","volume":"389","author":"J\u00f8rgensen KK","year":"2017","unstructured":"J\u00f8rgensen KK, Olsen IC, Goll GL, et al.. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial. Lancet. 2017, 389:2304-16. 10.1016\/S0140-6736(17)30068-5","journal-title":"Lancet"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(23)00003-1","article-title":"The cost of inflammatory bowel disease in high-income settings: a Lancet Gastroenterology & Hepatology Commission","volume":"8","author":"Burisch J","year":"2023","unstructured":"Burisch J, Zhao M, Odes S, et al.. The cost of inflammatory bowel disease in high-income settings: a Lancet Gastroenterology & Hepatology Commission. Lancet Gastroenterol Hepatol. 2023, 8:458-92. 10.1016\/S2468-1253(23)00003-1","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606910","article-title":"Tofacitinib as induction and maintenance therapy for ulcerative colitis","volume":"376","author":"Sandborn WJ","year":"2017","unstructured":"Sandborn WJ, Su C, Sands BE, et al.. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2017, 376:1723-36. 10.1056\/NEJMoa1606910","journal-title":"N Engl J Med"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2033617","article-title":"Ozanimod as induction and maintenance therapy for ulcerative colitis","volume":"385","author":"Sandborn WJ","year":"2021","unstructured":"Sandborn WJ, Feagan BG, D'Haens G, et al.. Ozanimod as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2021, 385:1280-91. 10.1056\/NEJMoa2033617","journal-title":"N Engl J Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/509752-how-biologics-are-changing-the-global-burden-of-inflammatory-bowel-disease-a-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T12:37:32Z","timestamp":1783600652000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/509752-how-biologics-are-changing-the-global-burden-of-inflammatory-bowel-disease-a-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,9]]},"references-count":28,"URL":"https:\/\/doi.org\/10.7759\/cureus.112332","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7,9]]}}}